Preclinical studies show that FAK blockade using pharmacological inhibitors or siRNA knockdown reduces BCSC-like properties, including ALDH1 activity, EMT, mammosphere-forming ability and tumor-initiating capacity in breast cancer in vitro and in vivo [25, 26]. The gene discussed is PTK2; the disease is breast carcinoma.